Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A18 in advanced solid tumors
NCT06985368Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIBP-A18 in solid tumor malignancy, sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events, Serious Adverse Events and 5 more. Started Jun 2025; status: recruiting.
02
Drugs
SIBP-A18
03
Conditions
solid tumor malignancy
Beyond the preview
Go deeper on NCT06985368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985368.